⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6796029 | 1.00 | — | — | |
| SCHEMBL15061681 | 1.00 | — | — | |
| SCHEMBL4193121 | 0.79 | BACE1 (0.30) | — | |
| SCHEMBL13008014 | 0.76 | — | — | |
| SCHEMBL13900150 | 0.76 | GLA (0.32) | — | |
| SCHEMBL21874932 | 0.75 | PTPN1 (0.33) | — | |
| SCHEMBL4186128 | 0.73 | GAA (0.34) | — | |
| SCHEMBL5112776 | 0.73 | GAA (0.34) | — | |
| SCHEMBL146063 | 0.72 | GLA (0.37) | — | |
| SCHEMBL15636224 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025105354-A1 | COMPOSITION FOR SEMICONDUCTOR PRODUCTION | 三菱瓦斯化学株式会社 | 2025-05-22 | — | — | WO | claimed |
| WO-2025105354-A1 | COMPOSITION FOR SEMICONDUCTOR PRODUCTION | 三菱瓦斯化学株式会社 | 2025-05-22 | — | — | WO | disclosed |
| CN-115702508-A | Lithium ion battery having anode comprising blend of intercalation-type anode material and conversion-type anode material | 新罗纳米技术有限公司 | 2023-02-14 | — | — | CN | disclosed |
| US-10464952-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180291039-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-10-11 | — | — | US | disclosed |
| EP-2903609-B1 | PROTECTED SUCCINATES FOR ENHANCING MITOCHONDRIAL ATP-PRODUCTION | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-12-06 | — | — | EP | disclosed |
| WO-2017100537-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2017-06-15 | — | — | WO | disclosed |
| US-9670175-B2 | Protected succinates for enhancing mitochondrial ATP-production | Neurovive Pharmaceuticals AB (SE) | 2017-06-06 | — | — | US | disclosed |
| US-20150259317-A1 | PROTECTED SUCCINATES FOR ENHANCING MITOCHONDRIAL ATP-PRODUCTION | MITOPHARM LTD (GB) | 2015-09-17 | — | — | US | disclosed |
| US-7795261-B2 | Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| US-7521579-B2 | Process for the preparation of alpha hydroxycarboxylic acid amides | SYNGENTA CROP PROTECTION, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521579-B2 | Process for the preparation of alpha hydroxycarboxylic acid amides | SYNGENTA CROP PROTECTION, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7157460-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040116709-A1 | Process for producing optically active n-aryl-1-amino-2-propanol derivatives | KANEKA CORPORATION (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1367053-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE N-ARYL-1-AMINO-2-PROPANOL DERIVATIVES | KANEKA CORPORATION (JP) | 2003-12-03 | — | — | EP | disclosed |